SMOOSE

Publikationen

2018

Cun, Y., Yang, T.-P., Achter, V., Lang, U., Peifer, M., 2018. Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust. Nature Protocols 13, 1488–1501. doi.org/10.1038/nprot.2018.033

Drapkin, B.J., George, J., Christensen, C.L., Mino-Kenudson, M., Dries, R., Sundaresan, T., Phat, S., Myers, D.T., Zhong, J., Igo, P., Hazar-Rethinam, M.H., Licausi, J.A., Gomez-Caraballo, M., Kem, M., Jani, K.N., Azimi, R., Abedpour, N., Menon, R., Lakis, S., Heist, R.S., Büttner, R., Haas, S., Sequist, L.V., Shaw, A.T., Wong, K.-K., Hata, A.N., Toner, M., Maheswaran, S., Haber, D.A., Peifer, M., Dyson, N., Thomas, R.K., Farago, A.F., 2018. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov 8, 600–615. doi.org/10.1158/2159-8290.CD-17-0935

George, J., Walter, V., Peifer, M., Alexandrov, L.B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T.M., Ardin, M., Leblay, N., Byrnes, G., Sun, R., De Reynies, A., McLeer-Florin, A., Bosco, G., Malchers, F., Menon, R., Altmüller, J., Becker, C., Nürnberg, P., Achter, V., Lang, U., Schneider, P.M., Bogus, M., Soloway, M.G., Wilkerson, M.D., Cun, Y., McKay, J.D., Moro-Sibilot, D., Brambilla, C.G., Lantuejoul, S., Lemaitre, N., Soltermann, A., Weder, W., Tischler, V., Brustugun, O.T., Lund-Iversen, M., Helland, Å., Solberg, S., Ansén, S., Wright, G., Solomon, B., Roz, L., Pastorino, U., Petersen, I., Clement, J.H., Sänger, J., Wolf, J., Vingron, M., Zander, T., Perner, S., Travis, W.D., Haas, S.A., Olivier, M., Foll, M., Büttner, R., Hayes, D.N., Brambilla, E., Fernandez-Cuesta, L., Thomas, R.K., 2018. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 9, 1048. doi.org/10.1038/s41467-018-03099-x

Herling, C.D., Abedpour, N., Weiss, J., Schmitt, A., Jachimowicz, R.D., Merkel, O., Cartolano, M., Oberbeck, S., Mayer, P., Berg, V., Thomalla, D., Kutsch, N., Stiefelhagen, M., Cramer, P., Wendtner, C.-M., Persigehl, T., Saleh, A., Altmüller, J., Nürnberg, P., Pallasch, C., Achter, V., Lang, U., Eichhorst, B., Castiglione, R., Schäfer, S.C., Büttner, R., Kreuzer, K.-A., Reinhardt, H.C., Hallek, M., Frenzel, L.P., Peifer, M., 2018. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun 9, 727. doi.org/10.1038/s41467-018-03170-7

Knittel, G., Rehkämper, T., Nieper, P., Schmitt, A., Flümann, R., Reinhardt, H.C., 2018. DNA damage pathways and B-cell lymphomagenesis. Curr. Opin. Hematol. 25, 315–322. doi.org/10.1097/MOH.0000000000000433

Macheleidt, I.F., Dalvi, P.S., Lim, S.-Y., Meemboor, S., Meder, L., Käsgen, O., Müller, M., Kleemann, K., Wang, L., Nürnberg, P., Rüsseler, V., Schäfer, S.C., Mahabir, E., Büttner, R., Odenthal, M., 2018. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations. Mol Oncol. doi.org/10.1002/1878-0261.12382

Meder, L., König, K., Dietlein, F., Macheleidt, I., Florin, A., Ercanoglu, M.S., Rommerscheidt-Fuss, U., Koker, M., Schön, G., Odenthal, M., Klein, F., Büttner, R., Schulte, J.H., Heukamp, L.C., Ullrich, R.T., 2018a. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene 37, 2746–2756. doi.org/10.1038/s41388-018-0158-7

Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., Riedel, R., Florin, A., Golfmann, K., Schlößer, H.A., Odenthal, M., Buettner, R., Wolf, J., Hallek, M., Herling, M., von Bergwelt-Baildon, M., Reinhardt, H.C., Ullrich, R.T., 2018b. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 78, 4270–4281. doi.org/10.1158/0008-5472.CAN-17-2176

Plenker, D., Bertrand, M., de Langen, A.J., Riedel, R., Lorenz, C., Scheel, A.H., Müller, J., Brägelmann, J., Daßler-Plenker, J., Kobe, C., Persigehl, T., Kluge, A., Wurdinger, T., Schellen, P., Hartmann, G., Zacherle, T., Menon, R., Thunnissen, E., Büttner, R., Griesinger, F., Wolf, J., Heukamp, L., Sos, M.L., Heuckmann, J.M., 2018. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin. Cancer Res. 24, 1337–1343. doi.org/10.1158/1078-0432.CCR-17-3001

Schmitt, A., Feldmann, G., Zander, T., Reinhardt, H.C., 2018. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncol Res Treat 41, 619–625. doi.org/10.1159/000493401

Tesch, R., Becker, C., Müller, M.P., Beck, M.E., Quambusch, L., Getlik, M., Lategahn, J., Uhlenbrock, N., Costa, F.N., Polêto, M.D., de Sena Murteira Pinheiro, P., Rodrigues, D.A., Sant’Anna, C.M.R., Ferreira, F.F., Verli, H., Fraga, C.A.M., Rauh, D., 2018. An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angew. Chem. Int. Ed. Engl. doi.org/10.1002/anie.201804917

Wiedemann, B., Weisner, J., Rauh, D., 2018. Chemical modulation of transcription factors. Medchemcomm 9, 1249–1272. doi.org/10.1039/c8md00273h

Wolle, P., Müller, M.P., Rauh, D., 2018a. Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level. ACS Chem. Biol. 13, 496–499. doi.org/10.1021/acschembio.8b00153

Wolle, P., Weisner, J., Keul, M., Landel, I., Lategahn, J., Rauh, D., 2018b. RASPELD to Perform High-End Screening in an Academic Environment Toward the Development of Cancer Therapeutics. ChemMedChem. doi.org/10.1002/cmdc.201800477

2017

Amer, W., Toth, C., Vassella, E., Meinrath, J., Koitzsch, U., Arens, A., Huang, J., Eischeid, H., Adam, A., Buettner, R., Scheel, A., Schaefer, S.C., Odenthal, M., 2017. Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome. Sci Rep 7, 11069. doi.org/10.1038/s41598-017-11345-3

Brägelmann, J., Dammert, M.A., Dietlein, F., Heuckmann, J.M., Choidas, A., Böhm, S., Richters, A., Basu, D., Tischler, V., Lorenz, C., Habenberger, P., Fang, Z., Ortiz-Cuaran, S., Leenders, F., Eickhoff, J., Koch, U., Getlik, M., Termathe, M., Sallouh, M., Greff, Z., Varga, Z., Balke-Want, H., French, C.A., Peifer, M., Reinhardt, H.C., Örfi, L., Kéri, G., Ansén, S., Heukamp, L.C., Büttner, R., Rauh, D., Klebl, B.M., Thomas, R.K., Sos, M.L., 2017. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports 20, 2833–2845. doi.org/10.1016/j.celrep.2017.08.082

Bührmann, M., Wiedemann, B.M., Müller, M.P., Hardick, J., Ecke, M., Rauh, D., 2017. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PLoS ONE 12, e0184627. doi.org/10.1371/journal.pone.0184627

Büttner, R., Wolf, J., Thomas, R.K., Sos, M.L., 2017. Resistance Mechanisms to AZD9291 and Rociletinib-Response. Clin. Cancer Res. 23, 3967–3968. doi.org/10.1158/1078-0432.CCR-17-0948

Doerr, F., George, J., Schmitt, A., Beleggia, F., Rehkämper, T., Hermann, S., Walter, V., Weber, J.-P., Thomas, R.K., Wittersheim, M., Büttner, R., Persigehl, T., Reinhardt, H.C., 2017. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Sci Rep 7, 15511. doi.org/10.1038/s41598-017-15840-5

Engel, J., Smith, S., Lategahn, J., Tumbrink, H.L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., Baumann, M., Schultz-Fademrecht, C., Günther, G., Hengstler, J.G., Rauh, D., 2017. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. J. Med. Chem. 60, 7725–7744. doi.org/10.1021/acs.jmedchem.7b00515

George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A.H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., Peifer, M., Jang, S.J., Petersen, I., Büttner, R., Harris, C.C., Yokota, J., Thomas, R.K., Kohno, T., 2017. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin. Cancer Res. 23, 1220–1226. doi.org/10.1158/1078-0432.CCR-16-1069

Henssen, A.G., Odersky, A., Szymansky, A., Seiler, M., Althoff, K., Beckers, A., Speleman, F., Schäfers, S., De Preter, K., Astrahanseff, K., Struck, J., Schramm, A., Eggert, A., Bergmann, A., Schulte, J.H., 2017. Targeting tachykinin receptors in neuroblastoma. Oncotarget 8, 430–443. doi.org/10.18632/oncotarget.13440

Kaitsiotou, H., Keul, M., Hardick, J., Mühlenberg, T., Ketzer, J., Ehrt, C., Krüll, J., Medda, F., Koch, O., Giordanetto, F., Bauer, S., Rauh, D., 2017. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. J. Med. Chem. 60, 8801–8815. doi.org/10.1021/acs.jmedchem.7b00841

Knittel, G., Rehkämper, T., Korovkina, D., Liedgens, P., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P.-H., Wunderlich, F.T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., P Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T., Reinhardt, H.C., 2017. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun 8, 153. doi.org/10.1038/s41467-017-00210-6

Lim, S.-Y., Macheleidt, I., Dalvi, P., Schäfer, S.C., Kerick, M., Ozretić, L., Ortiz-Cuaran, S., George, J., Merkelbach-Bruse, S., Wolf, J., Timmermann, B., Thomas, R.K., Schweiger, M.R., Buettner, R., Odenthal, M., 2017. LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells. Sci Rep 7, 10292. doi.org/10.1038/s41598-017-09554-x

Malchers, F., Ercanoglu, M., Schütte, D., Castiglione, R., Tischler, V., Michels, S., Dahmen, I., Brägelmann, J., Menon, R., Heuckmann, J.M., George, J., Ansén, S., Sos, M.L., Soltermann, A., Peifer, M., Wolf, J., Büttner, R., Thomas, R.K., 2017. Mechanisms of Primary Drug Resistance inFGFR1-Amplified Lung Cancer. Clin. Cancer Res. 23, 5527–5536. doi.org/10.1158/1078-0432.CCR-17-0478

Mollaoglu, G., Guthrie, M.R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P.M., Marx, A., George, J., Heinen, C., Chalishazar, M.D., Cheng, H., Ireland, A.S., Denning, K.E., Mukhopadhyay, A., Vahrenkamp, J.M., Berrett, K.C., Mosbruger, T.L., Wang, J., Kohan, J.L., Salama, M.E., Witt, B.L., Peifer, M., Thomas, R.K., Gertz, J., Johnson, J.E., Gazdar, A.F., Wechsler-Reya, R.J., Sos, M.L., Oliver, T.G., 2017. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell. doi.org/10.1016/j.ccell.2016.12.005

Plenker, D., Riedel, M., Brägelmann, J., Dammert, M.A., Chauhan, R., Knowles, P.P., Lorenz, C., Keul, M., Bührmann, M., Pagel, O., Tischler, V., Scheel, A.H., Schütte, D., Song, Y., Stark, J., Mrugalla, F., Alber, Y., Richters, A., Engel, J., Leenders, F., Heuckmann, J.M., Wolf, J., Diebold, J., Pall, G., Peifer, M., Aerts, M., Gevaert, K., Zahedi, R.P., Buettner, R., Shokat, K.M., McDonald, N.Q., Kast, S.M., Gautschi, O., Thomas, R.K., Sos, M.L., 2017. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med 9. doi.org/10.1126/scitranslmed.aah6144

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Engesser, A., Kahlert, Y., Volland, R., Bartenhagen, C., Simon, T., Berthold, F., Hero, B., Faldum, A., Fischer, M., 2017. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia 19, 982–990. doi.org/10.1016/j.neo.2017.09.006

Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M., Reinhardt, H.C., 2017. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Res. 77, 3040–3056. doi.org/10.1158/0008-5472.CAN-16-3398

Weischenfeldt, J., Dubash, T., Drainas, A.P., Mardin, B.R., Chen, Y., Stütz, A.M., Waszak, S.M., Bosco, G., Halvorsen, A.R., Raeder, B., Efthymiopoulos, T., Erkek, S., Siegl, C., Brenner, H., Brustugun, O.T., Dieter, S.M., Northcott, P.A., Petersen, I., Pfister, S.M., Schneider, M., Solberg, S.K., Thunissen, E., Weichert, W., Zichner, T., Thomas, R., Peifer, M., Helland, A., Ball, C.R., Jechlinger, M., Sotillo, R., Glimm, H., Korbel, J.O., 2017. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat. Genet. 49, 65–74. doi.org/10.1038/ng.3722

2016

Becker, C., Öcal, S., Nguyen, H.D., Phan, T., Keul, M., Simard, J.R., Rauh, D., 2016. Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR. ChemBioChem 17, 990–994. doi.org/10.1002/cbic.201600115

Bunn, P.A., Minna, J.D., Augustyn, A., Gazdar, A.F., Ouadah, Y., Krasnow, M.A., Berns, A., Brambilla, E., Rekhtman, N., Massion, P.P., Niederst, M., Peifer, M., Yokota, J., Govindan, R., Poirier, J.T., Byers, L.A., Wynes, M.W., McFadden, D.G., MacPherson, D., Hann, C.L., Farago, A.F., Dive, C., Teicher, B.A., Peacock, C.D., Johnson, J.E., Cobb, M.H., Wendel, H.-G., Spigel, D., Sage, J., Yang, P., Pietanza, M.C., Krug, L.M., Heymach, J., Ujhazy, P., Zhou, C., Goto, K., Dowlati, A., Christensen, C.L., Park, K., Einhorn, L.H., Edelman, M.J., Giaccone, G., Gerber, D.E., Salgia, R., Owonikoko, T., Malik, S., Karachaliou, N., Gandara, D.R., Slotman, B.J., Blackhall, F., Goss, G., Thomas, R., Rudin, C.M., Hirsch, F.R., 2016. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 11, 453–474. doi.org/10.1016/j.jtho.2016.01.012

Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz-Fademrecht, C., Zahedi, R.P., Bauer, S., Rauh, D., 2016a. Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. Angew. Chem. n/a-n/a. doi.org/10.1002/ange.201605011

Engel, J., Lategahn, J., Rauh, D., 2016b. Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. ACS Med Chem Lett 7, 2–5. doi.org/10.1021/acsmedchemlett.5b00475

Fernández-Majada, V., Welz, P.-S., Ermolaeva, M.A., Schell, M., Adam, A., Dietlein, F., Komander, D., Büttner, R., Thomas, R.K., Schumacher, B., Pasparakis, M., 2016. The tumour suppressor CYLD regulates the p53 DNA damage response. Nat Commun 7, 12508. doi.org/10.1038/ncomms12508

George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A.H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., Peifer, M., Jang, S.J., Petersen, I., Büttner, R., Harris, C.C., Yokota, J., Thomas, R.K., Kohno, T., 2016. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin. Cancer Res. doi.org/10.1158/1078-0432.CCR-16-1069

Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M.E., Eggert, A., Cvitkovic, E., Schulte, J.H., 2016. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clin. Cancer Res. 22, 2470–2481. doi.org/10.1158/1078-0432.CCR-15-1449

Ikram, F., Ackermann, S., Kahlert, Y., Volland, R., Roels, F., Engesser, A., Hertwig, F., Kocak, H., Hero, B., Dreidax, D., Henrich, K.-O., Berthold, F., Nürnberg, P., Westermann, F., Fischer, M., 2016. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol 10, 344–359. doi.org/10.1016/j.molonc.2015.10.020

Meder, L., König, K., Ozretić, L., Schultheis, A.M., Ueckeroth, F., Ade, C.P., Albus, K., Boehm, D., Rommerscheidt-Fuss, U., Florin, A., Buhl, T., Hartmann, W., Wolf, J., Merkelbach-Bruse, S., Eilers, M., Perner, S., Heukamp, L.C., Buettner, R., 2016. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int. J. Cancer 138, 927–938. doi.org/10.1002/ijc.29835

Ortiz-Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A.H., Fernandez-Cuesta, L., Meder, L., Lovly, C.M., Persigehl, T., Merkelbach-Bruse, S., Bos, M., Michels, S., Fischer, R., Albus, K., König, K., Schildhaus, H.-U., Fassunke, J., Ihle, M.A., Pasternack, H., Heydt, C., Becker, C., Altmüller, J., Ji, H., Müller, C., Florin, A., Heuckmann, J.M., Nuernberg, P., Ansén, S., Heukamp, L.C., Berg, J., Pao, W., Peifer, M., Buettner, R., Wolf, J., Thomas, R.K., Sos, M.L., 2016. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin. Cancer Res. 22, 4837–4847. doi.org/10.1158/1078-0432.CCR-15-1915

Radi, M., Schneider, R., Fallacara, A.L., Botta, L., Crespan, E., Tintori, C., Maga, G., Kissova, M., Calgani, A., Richters, A., Musumeci, F., Rauh, D., Schenone, S., 2016. A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant. Bioorg. Med. Chem. Lett. 26, 3436–3440. doi.org/10.1016/j.bmcl.2016.06.051

Ribeiro, D., Klarqvist, M.D.R., Westermark, U.K., Oliynyk, G., Dzieran, J., Kock, A., Savatier Banares, C., Hertwig, F., Johnsen, J.I., Fischer, M., Kogner, P., Lovén, J., Arsenian Henriksson, M., 2016. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Rep 16, 979–993. doi.org/10.1016/j.celrep.2016.06.052

Thompson, D., Vo, K.T., London, W.B., Fischer, M., Ambros, P.F., Nakagawara, A., Brodeur, G.M., Matthay, K.K., DuBois, S.G., 2016. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer 122, 935–945. doi.org/10.1002/cncr.29848

Weiskopf, K., Jahchan, N.S., Schnorr, P.J., Cristea, S., Ring, A.M., Maute, R.L., Volkmer, A.K., Volkmer, J.-P., Liu, J., Lim, J.S., Yang, D., Seitz, G., Nguyen, T., Wu, D., Jude, K., Guerston, H., Barkal, A., Trapani, F., George, J., Poirier, J.T., Gardner, E.E., Miles, L.A., de Stanchina, E., Lofgren, S.M., Vogel, H., Winslow, M.M., Dive, C., Thomas, R.K., Rudin, C.M., van de Rijn, M., Majeti, R., Garcia, K.C., Weissman, I.L., Sage, J., 2016. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. 126, 2610–2620. http://doi.org/10.1172/JCI81603

2015

Basu, D., Richters, A., Rauh, D., 2015. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorg. Med. Chem. 23, 2767–2780. doi.org/10.1016/j.bmc.2015.04.038

Carter, D.R., Murray, J., Cheung, B.B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A.J., Issaeva, N., Biktasova, A., Atmadibrata, B., Sun, Y., Sokolowski, N., Ling, D., Kim, P.Y., Webber, H., Clark, A., Ruhle, M., Liu, B., Oberthuer, A., Fischer, M., Byrne, J., Saletta, F., Thwe, L.M., Purmal, A., Haderski, G., Burkhart, C., Speleman, F., De Preter, K., Beckers, A., Ziegler, D.S., Liu, T., Gurova, K.V., Gudkov, A.V., Norris, M.D., Haber, M., Marshall, G.M., 2015. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7, 312ra176. doi.org/10.1126/scitranslmed.aab1803

Dietlein, F., Kalb, B., Jokic, M., Noll, E.M., Strong, A., Tharun, L., Ozretić, L., Künstlinger, H., Kambartel, K., Randerath, W.J., Jüngst, C., Schmitt, A., Torgovnick, A., Richters, A., Rauh, D., Siedek, F., Persigehl, T., Mauch, C., Bartkova, J., Bradley, A., Sprick, M.R., Trumpp, A., Rad, R., Saur, D., Bartek, J., Wolf, J., Büttner, R., Thomas, R.K., Reinhardt, H.C., 2015. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell 162, 146–159. doi.org/10.1016/j.cell.2015.05.053

Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer-Wrangowski, S., Grütter, C., Uhlenbrock, N., Krüll, J., Schaumann, N., Eppmann, S., Kibies, P., Hoffgaard, F., Heil, J., Menninger, S., Ortiz-Cuaran, S., Heuckmann, J.M., Tinnefeld, V., Zahedi, R.P., Sos, M.L., Schultz-Fademrecht, C., Thomas, R.K., Kast, S.M., Rauh, D., 2015. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. J. Med. Chem. 58, 6844–6863. doi.org/10.1021/acs.jmedchem.5b01082

Fang, Z., Simard, J.R., Plenker, D., Nguyen, H.D., Phan, T., Wolle, P., Baumeister, S., Rauh, D., 2015. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors. ACS Chem. Biol. 10, 279–288. doi.org/10.1021/cb500355c

Fernandez-Cuesta, L., Sun, R., Menon, R., George, J., Lorenz, S., Meza-Zepeda, L.A., Peifer, M., Plenker, D., Heuckmann, J.M., Leenders, F., Zander, T., Dahmen, I., Koker, M., Schöttle, J., Ullrich, R.T., Altmüller, J., Becker, C., Nürnberg, P., Seidel, H., Böhm, D., Göke, F., Ansén, S., Russell, P.A., Wright, G.M., Wainer, Z., Solomon, B., Petersen, I., Clement, J.H., Sänger, J., Brustugun, O.-T., Helland, Å., Solberg, S., Lund-Iversen, M., Buettner, R., Wolf, J., Brambilla, E., Vingron, M., Perner, S., Haas, S.A., Thomas, R.K., 2015. Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol. 16, 7. doi.org/10.1186/s13059-014-0558-0

Fey, D., Halasz, M., Dreidax, D., Kennedy, S.P., Hastings, J.F., Rauch, N., Munoz, A.G., Pilkington, R., Fischer, M., Westermann, F., Kolch, W., Kholodenko, B.N., Croucher, D.R., 2015. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal 8, ra130. doi.org/10.1126/scisignal.aab0990

George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., Müller, C., Dahmen, I., Jahchan, N.S., Park, K.-S., Yang, D., Karnezis, A.N., Vaka, D., Torres, A., Wang, M.S., Korbel, J.O., Menon, R., Chun, S.-M., Kim, D., Wilkerson, M., Hayes, N., Engelmann, D., Pützer, B., Bos, M., Michels, S., Vlasic, I., Seidel, D., Pinther, B., Schaub, P., Becker, C., Altmüller, J., Yokota, J., Kohno, T., Iwakawa, R., Tsuta, K., Noguchi, M., Muley, T., Hoffmann, H., Schnabel, P.A., Petersen, I., Chen, Y., Soltermann, A., Tischler, V., Choi, C., Kim, Y.-H., Massion, P.P., Zou, Y., Jovanovic, D., Kontic, M., Wright, G.M., Russell, P.A., Solomon, B., Koch, I., Lindner, M., Muscarella, L.A., la Torre, A., Field, J.K., Jakopovic, M., Knezevic, J., Castaños-Vélez, E., Roz, L., Pastorino, U., Brustugun, O.-T., Lund-Iversen, M., Thunnissen, E., Köhler, J., Schuler, M., Botling, J., Sandelin, M., Sanchez-Cespedes, M., Salvesen, H.B., Achter, V., Lang, U., Bogus, M., Schneider, P.M., Zander, T., Ansén, S., Hallek, M., Wolf, J., Vingron, M., Yatabe, Y., Travis, W.D., Nürnberg, P., Reinhardt, C., Perner, S., Heukamp, L., Büttner, R., Haas, S.A., Brambilla, E., Peifer, M., Sage, J., Thomas, R.K., 2015. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53. doi.org/10.1038/nature14664

Lindner, S., Bachmann, H.S., Odersky, A., Schaefers, S., Klein-Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J.H., 2015. Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep 3, 443–446. doi.org/10.3892/br.2015.463

Mayer-Wrangowski, S.C., Rauh, D., 2015. Monitoring ligand-induced conformational changes for the identification of estrogen receptor agonists and antagonists. Angew. Chem. Int. Ed. Engl. 54, 4379–4382. doi.org/10.1002/anie.201410148

Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J.L., Sand, F., Heuckmann, J.M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmüller, J., Nürnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K.-O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M.R., Savelyeva, L., Watkins, S.C., Shao, C., Bell, E., Höfer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Büttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J.H., Herrmann, C., O’Sullivan, R.J., Westermann, F., Thomas, R.K., Fischer, M., 2015. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704. doi.org/10.1038/nature14980

Richters, A., Basu, D., Engel, J., Ercanoglu, M.S., Balke-Want, H., Tesch, R., Thomas, R.K., Rauh, D., 2015. Identification and further development of potent TBK1 inhibitors. ACS Chem. Biol. 10, 289–298. doi.org/10.1021/cb500908d

Scheffler, M., Merkelbach-Bruse, S., Bos, M., Fassunke, J., Gardizi, M., Michels, S., Groneck, L., Schultheis, A.M., Malchers, F., Leenders, F., Kobe, C., König, K., Heukamp, L.C., Sos, M.L., Thomas, R.K., Büttner, R., Wolf, J., 2015. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. J Thorac Oncol 10, e40-43. doi.org/10.1097/JTO.0000000000000503

Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.-O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte, J.H., 2015. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877. doi.org/10.1038/ng.3349

Schultheis, A.M., Scheel, A.H., Ozretić, L., George, J., Thomas, R.K., Hagemann, T., Zander, T., Wolf, J., Buettner, R., 2015. PD-L1 expression in small cell neuroendocrine carcinomas. Eur. J. Cancer 51, 421–426. doi.org/10.1016/j.ejca.2014.12.006

Weisner, J., Gontla, R., van der Westhuizen, L., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., Jendrossek, V., Pelly, S.C., Bauer, S., van Otterlo, W.A.L., Rauh, D., 2015. Covalent-Allosteric Kinase Inhibitors. Angew. Chem. Int. Ed. Engl. 54, 10313–10316. doi.org/10.1002/anie.201502142

2014

 

Richters, A., Nguyen, H.D., Phan, T., Simard, J.R., Grütter, C., Engel, J., Rauh, D., 2014. Identification of type II and III DDR2 inhibitors. J. Med. Chem. 57, 4252–4262. doi.org/10.1021/jm500167q